Follow Us:
Abatacept

Orencia

Abatacept

Abatacept is a biologic disease-modifying antirheumatic drug (DMARD) used to treat autoimmune conditions such as rheumatoid arthritis, psoriatic arthritis, and polyarticular juvenile idiopathic arthritis. It works by modulating T-cell activation, helping reduce inflammation, joint damage, and disease activity. Abatacept is administered by intravenous infusion or subcutaneous injection under medical supervision.

Dosage Form:
Dosage Strength:
CAS No.: 332348-12-6
Status:
Manufacturer:
Group: Anti-rheumatic drugs
Sub Group: Biological Response Modifiers
Class: TNF-Alpha Inhibitors

Uses of Abatacept

Abatacept was historically used as a respiratory medicine for the symptomatic management of certain respiratory conditions. Its former uses included:

  • Rheumatoid arthritis: Reduce joint inflammation, pain, swelling and progressive joint damage.
  • Psoriatic arthritis: Control joint inflammation and improve symptoms associated with psoriatic disease.
  • Ankylosing spondylitis: Reduce spinal inflammation, stiffness and disease activity.
  • Plaque psoriasis: Treat moderate to severe psoriasis in appropriate patients.
  • Crohn's disease: Selected TNF inhibitors, including infliximab and adalimumab, help control intestinal inflammation.
  • Ulcerative colitis: Certain TNF inhibitors are used to manage moderate to severe inflammatory disease.
  • Juvenile idiopathic arthritis: Selected TNF inhibitors are used to manage specific forms of inflammatory arthritis in children.
  • Hidradenitis suppurativa: Adalimumab is used for selected patients with moderate to severe disease.

Contraindication of Abatacept

Abatacept was historically subject to specific precautions during administration to ensure patient safety. Its former precautions included:

  • Known hypersensitivity to the specific TNF-alpha inhibitor or its formulation components.
  • Active serious infections, including active tuberculosis.
  • Untreated serious opportunistic infections.
  • Moderate to severe heart failure, particularly for certain TNF inhibitors.
  • Previous serious allergic or infusion-related reactions to the prescribed biological agent.
  • Certain demyelinating disorders may make TNF-alpha inhibitor treatment unsuitable.
  • Additional contraindications may apply depending on the individual medicine and patient's medical history.

Precautions for Abatacept

Abatacept was majorly subjected to specific precautions during administration to ensure patient safety. Its former precautions included:

  • Infection risk: TNF-alpha inhibitors can increase susceptibility to serious bacterial, fungal and opportunistic infections.
  • Tuberculosis screening: Patients should be screened for active and latent tuberculosis before treatment because these medicines can reactivate latent infection.
  • Hepatitis B: Screen for hepatitis B infection before treatment because viral reactivation may occur.
  • Heart failure: Use cautiously or avoid certain TNF inhibitors in patients with moderate to severe heart failure.
  • Neurological conditions: Patients with existing or suspected demyelinating disorders, such as multiple sclerosis, require careful assessment.
  • Blood disorders: Monitor for unexplained anaemia, leukopenia, thrombocytopenia or other blood abnormalities.
  • Malignancy risk: Assess patients with a history of malignancy and monitor for unusual symptoms during prolonged treatment.
  • Vaccination: Live vaccines are generally avoided during treatment. Vaccination status should be reviewed before starting therapy.
  • Pregnancy and breastfeeding: Safety varies between individual agents. Treatment decisions should consider the specific medicine and clinical circumstances.

Drug Interactions for Abatacept

Potential drug interactions were historically documented when Abatacept was prescribed alongside certain medications. These included:

  • Other biological DMARDs: Combining TNF inhibitors with other biological immunosuppressants, such as anakinra or abatacept, may increase the risk of serious infections.
  • Methotrexate: Frequently prescribed alongside certain TNF inhibitors to improve treatment response, particularly in rheumatoid arthritis; monitoring remains necessary.
  • Corticosteroids: Concurrent use may increase immunosuppression and the risk of serious infections.
  • Cyclosporine and tacrolimus: Combining these medicines with TNF inhibitors may increase the risk of excessive immunosuppression.
  • Live vaccines: Live vaccines may cause infections in patients receiving TNF-alpha inhibitors and are generally avoided during treatment.
  • Warfarin: Changes in inflammatory activity and concomitant medication use may affect anticoagulant response; monitor INR when clinically appropriate.
  • Immunosuppressive medicines: Combination treatment requires careful assessment because of increased infection and other adverse-effect risks.

Frequently Asked Questions

The most frequently asked questions focus on import, export, documentations, and regulation for Abatacept.

The Abatacept is a pharmaceutical active pharmaceutical ingredient (API) used in manufacturing of Abatacept.

: Provides active pharmaceutical ingredients (APIs), customized production, and OEM/ODM services with research and technical cooperation across Europe, the USA, and India via Primeera Healthcare.

  • Therapeutic Goods Administration (TGA):
  • US Food and Drug Administration (USFDA):
  • European Medicines Agency (EMA):
  • African Medicines Agency (AMA):
  • National Medical Products Administration (NMPA):
  • Central Drugs Standard Control Organization (CDSCO):

Primeera Healthcare Private Limited can provide import coordination and pharmaceutical documentation assistance for Abatacept, subject to confirmation of its current regulatory status and eligibility for import into India.

Documentation Required for Abatacept Import

The import of medicines into India is regulated by the Central Drugs Standard Control Organisation (CDSCO) under the Drugs and Cosmetics Act, 1940, and the Drugs and Cosmetics Rules, 1945. The regulatory requirements depend on whether the product is an active pharmaceutical ingredient (API), a finished formulation, or an unapproved medicine intended for an individual patient's treatment.

Import Regulations and dcoumentation for Abatacept

  • Import Documentation Assistance:
    Support with organising commercial invoices, packing lists, manufacturer details, product specifications, certificates of analysis, and other relevant documents required for regulatory review and customs processing.

  • Regulatory Coordination:
    Assistance with identifying applicable CDSCO requirements, import authorisations, and documentation procedures, subject to the product's regulatory status and the proposed import route.
  • Shipping and Customs Coordination:
    Coordination with relevant logistics providers and customs professionals to organise shipment documentation and facilitate clearance where legally permitted.
  • Compliance Verification:
    Preliminary review of available product and shipment documentation to identify potential regulatory gaps before procurement or dispatch. Import arrangements will proceed only after the applicable permissions and restrictions have been verified.

Customs Clearance and Compliance Handling of Abatacept Import

Primeera Healthcare Private Limited can provide import coordination and pharmaceutical documentation assistance for Abatacept, subject to confirmation of its current regulatory status and eligibility for import into India.

Export Regulations and dcoumentation for Abatacept

The export of Abatacept from India is subject to applicable requirements under the Drugs and Cosmetics Act, 1940, the Drugs and Cosmetics Rules, 1945, and relevant export, customs, and destination-country regulations. Documentation requirements depend on whether the product is an active pharmaceutical ingredient (API), a finished pharmaceutical formulation, or a medicine intended for a specific market. Export eligibility and destination-country requirements must be verified before shipment.

Documentation Required for Abatacept Emport

  • Export Documentation Assistance:
    Assistance with organising commercial invoices, packing lists, manufacturer details, Abatacept specifications, certificates of analysis, and other supporting documents required for Abatacept export and customs processing.
  • Regulatory Coordination:
    Support in identifying applicable country specific Abatacept export requirements, relevant manufacturing and export authorisations, and destination-country registration or import approval requirements, subject to the Abatacept regulatory status.
  • Shipping and Customs Coordination:
    Coordination with logistics providers, freight forwarders, and customs professionals to organise shipping documentation, export declarations, and customs clearance procedures where legally permitted.
  • Compliance Verification:
    Preliminary review of available Abatacept documentation, labelling, Abatacept manufacturing information, and destination-market requirements to identify potential regulatory gaps before dispatch. Export arrangements will proceed only after the applicable restrictions and authorisations have been verified.

Customs Clearance and Compliance Handling of Abatacept Export

Primeera Healthcare Private Limited can provide pharmaceutical export documentation assistance, regulatory coordination, and shipping support for Abatacept, subject to confirmation of its export eligibility under applicable Indian regulations and the import requirements of the destination country.

Product Export Support

If you have any questions or need any help, contact our Support Team. We will get in touch with you within 24 hours from Monday to Friday between 9:00 and 10:00 CET.